Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation

References

• Swiers G, De Bruijn M, Speck NA. Hematopoietic stem cell emergence in the conceptus and the role of Runx1. Int J Dev Biol. 2010;54(6–7):1151–1163. doi: 10.1387/ijdb.103106gs
   PubMed Web of Science ®Google Scholar
• Sood R, Kamikubo Y, Liu P. Role of RUNX1 in hematological malignancies. Blood. 2017;129(15):2070–2082. doi: 10.1182/blood-2016-10-687830
   PubMed Web of Science ®Google Scholar
• Miyoshi H, Shimizu K, Kozu T, et al. T(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci U S A. 1991;88(23):10431–10434. doi: 10.1073/pnas.88.23.10431
   PubMed Web of Science ®Google Scholar
• Michaud J. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood. 2002;99(4):1364–1372. doi: 10.1182/blood.V99.4.1364
   PubMed Web of Science ®Google Scholar
• Gaidzik V I, Teleanu V, Papaemmanuil E, et al. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features. Leukemia. 2016 Nov;30(11):2160–2168. doi: 10.1038/leu.2016.126
   PubMed Web of Science ®Google Scholar
• Jalili M, Yaghmaie M, Ahmadvand M, et al. Prognostic value of RUNX1 mutations in AML: a meta-analysis. Asian Pac J Cancer Prev. 2018;Feb 26;19(2):325–329.
   PubMedGoogle Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi: 10.1182/blood-2016-03-643544
   PubMed Web of Science ®Google Scholar
• Ripperger T, Steinemann D, Gohring G, et al. A novel pedigree with heterozygous germline RUNX1 mutation causing familial MDS-related AML: can these families serve as a multistep model for leukemic transformation? Leukemia. 2009 Jul;23(7):1364–1366. doi: 10.1038/leu.2009.87
   PubMed Web of Science ®Google Scholar
• Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014 Feb;28(2):241–247. doi: 10.1038/leu.2013.336
   PubMed Web of Science ®Google Scholar
• Chen CY, Lin L, Tang JL, et al. RUNX1 gene mutation in primary myelodysplastic syndrome–the mutation can be detected early at diagnosis oracquired during disease progression and is associated with poor outcome. Br J Haematol. 2007 Nov;139(3):405–414. doi: 10.1111/j.1365-2141.2007.06811.x
   PubMed Web of Science ®Google Scholar
• Willatt L, Morgan SM, Shaffer LG, et al. ISCN 2009 an international system for human cytogenetic nomenclature. Hum Genet. 2009;126(4):603–604. doi: 10.1007/s00439-009-0726-6
   Google Scholar
• Rau R, Brown P. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. Hematol Oncol. 2009 Dec;27(4):171–181. doi: 10.1002/hon.904
   PubMed Web of Science ®Google Scholar
• Lin LI, Chen CY, Lin DT, et al. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res. 2005 Feb 15;11(4):1372–1379. doi: 10.1158/1078-0432.CCR-04-1816
   PubMed Web of Science ®Google Scholar
• Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999 May 1;93(9):3074–3080.
   PubMed Web of Science ®Google Scholar
• Hata T. Current diagnosis and treatment for myelodysplastc syndromes. Rinsho Ketsueki. 2017;58(4):373–380.
   PubMedGoogle Scholar
• Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364:2496–2506. doi: 10.1056/NEJMoa1013343
   PubMed Web of Science ®Google Scholar
• Sood R, Kamikubo Y, Liu P. Role of RUNX1 in hematological malignancies. Blood. 2017 Apr 13;129(15):2070–2082. doi: 10.1182/blood-2016-10-687830
   PubMed Web of Science ®Google Scholar
• Schnittger S, Dicker F, Kern W, et al. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood. 2011 Feb 24;117(8):2348–2357. doi: 10.1182/blood-2009-11-255976
   PubMed Web of Science ®Google Scholar
• Mangan JK1, Speck NA. RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making. Crit RevOncog. 2011;16(1-2):77–91.
   Google Scholar
• Sehgal AR, Gimotty PA, Zhao J, et al. DNMT3A mutational status affects the results of dose-escalated induction therapy in acute myelogenous leukemia. Clin Cancer Res. 2015 Apr 1;21(7):1614–1620. doi: 10.1158/1078-0432.CCR-14-0327
   PubMed Web of Science ®Google Scholar
• Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424–2433. doi: 10.1056/NEJMoa1005143
   PubMed Web of Science ®Google Scholar
• Tan M, Ng IKS, Chen Z, et al. Clinical implications of DNMT3A mutations in a Southeast Asian cohort of acute myeloi leukaemia patients. J Clin Pathol. 2017 Aug;70(8):669–676. doi: 10.1136/jclinpath-2016-204195
   PubMed Web of Science ®Google Scholar
• Rakheja D, Konoplev S, Medeiros LJ, et al. IDH mutations in acute myeloid leukemia. Hum Pathol. 2012;43(10):1541–1551. doi: 10.1016/j.humpath.2012.05.003
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Ravandi F, Agresta S, et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol. 2015;90(8):732–736. doi: 10.1002/ajh.24072
   PubMed Web of Science ®Google Scholar
• Yamaguchi S, Iwanaga E, Tokunaga K, et al. IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation. Eur J Haematol. 2014;92(6):471–477. doi: 10.1111/ejh.12271
   PubMed Web of Science ®Google Scholar
• Zhang T, Xu Y, Pan J, et al. High frequency of RUNX1 mutation in myelodysplastic syndrome patients with whole-arm translocation of der(1;7)(q10; p10). Leukemia. 2017 Oct;31(10):2257–2260. doi: 10.1038/leu.2017.228
   PubMed Web of Science ®Google Scholar
• Tefferi A, Idossa D, Lasho TL, et al. Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q). Blood Cancer J. 2017 Dec 18;7(12):658. doi: 10.1038/s41408-017-0017-8
   PubMedGoogle Scholar
• Fernandez-Mercado M, Burns A, Pellagatti A, et al. Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes. Haematologica. 2013 Dec;98(12):1856–1864. doi: 10.3324/haematol.2013.086686
   PubMed Web of Science ®Google Scholar